Senetek Expects To License Zeatin Technology In 12 To 18 Months
This article was originally published in The Rose Sheet
Executive Summary
Healthcare technology company Senetek expects to have a new patented anti-aging compound, Zeatin, ready to license to skin care manufacturers within the next 12 to 18 months, Chairman and CEO Frank Massino said, cautioning the timeframe will be directed by the timing of upcoming pre-clinical and clinical efficacy studies
You may also be interested in...
Beiersdorf/Senetek collaboration
Nivea skin care marketer Beiersdorf and Kinetin technology manufacturer Senetek form research agreement allowing Beiersdorf to conduct laboratory and in vivo evaluations of various skin care compounds owned by Senetek, two firms announce June 25. At the conclusion of each evaluation, Beiersdorf will have opportunity to enter licensing agreements to use the compound in its own products in global markets, while Senetek will maintain the right to license the compounds in markets not tapped by Beiersdorf, companies say. Beiersdorf's research and development programs in skin care are focused on protecting the skin from photodamage and treating skin aging, company adds. Senetek's Kinetin anti-aging technology also is used by Revlon and The Body Shop...
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle